量子点标记技术在脂蛋白相关磷脂酶A2中的应用
|
摘要
目的对脂蛋白磷脂酶A2(Lp-PLA2)量子点荧光检测试剂进行性能评价,判断其性能是否满足临床需求,并评价该试剂是否能够准确检测动脉粥样硬化患者的斑块稳定性。方法评估该检测试剂的日间和日内精密度、定量限和线性范围。结果该试剂盒日间和日内精密度均<10%,满足快速检测要求;定量限为35.1ng/mL,线性范围为35.1～784.3ng/mL。通过检测健康人群和存在不稳定斑块的动脉粥样硬化患者血清Lp-PLA2浓度,证明该方法能够对患者的动脉粥样斑块稳定性进行准确判断。结论 Lp-PLA2量子点荧光检测试剂具有良好的性能,且能够准确评估患者动脉粥样斑块稳定性,对于具有动脉粥样硬化危险因素患者的风险评估具有重要价值。
Objective To evaluate the performance of lipoprotein phospholipase A2(Lp-PLA2) quantum dot fluorescence detection reagent to determine whether its performance meets clinical requirements and to evaluate whether the reagent can accurately detect plaque stability in patients with atherosclerosis.Methods The daytime and intraday precision,limit of quantitation,and linear range of the test reagent were evaluated.Results The daytime and intraday precision of the kit was less than 10%,meeting the requirements of rapid detection.Limit of quantitation was 35.1 ng/mL and linear range was(35.1-784.3) ng/mL.By detecting the serum Lp-PLA2 concentration in healthy people and atherosclerotic patients with unstable plaques,it was proved that the method could accurately determine the stability of atherosclerotic plaque in patients.Conclusion Lp-PLA2 quantum dot fluorescence detection reagent has good performance and can accurately assess the stability of atherosclerotic plaque in patients.It is of great value for risk assessment of patients with risk factors for atherosclerosis.
Objective To evaluate the performance of lipoprotein phospholipase A2(Lp-PLA2) quantum dot fluorescence detection reagent to determine whether its performance meets clinical requirements and to evaluate whether the reagent can accurately detect plaque stability in patients with atherosclerosis.Methods The daytime and intraday precision,limit of quantitation,and linear range of the test reagent were evaluated.Results The daytime and intraday precision of the kit was less than 10%,meeting the requirements of rapid detection.Limit of quantitation was 35.1 ng/mL and linear range was(35.1-784.3) ng/mL.By detecting the serum Lp-PLA2 concentration in healthy people and atherosclerotic patients with unstable plaques,it was proved that the method could accurately determine the stability of atherosclerotic plaque in patients.Conclusion Lp-PLA2 quantum dot fluorescence detection reagent has good performance and can accurately assess the stability of atherosclerotic plaque in patients.It is of great value for risk assessment of patients with risk factors for atherosclerosis.
引文
[1]张慧信.动脉粥样硬化的病变及后果[J].心肺血管病杂志,1999,18(2):155.
[2]陈伟伟,王文,隋辉,等.《中国心血管病报告2016》要点解读[J].中华高血压杂志,2017,25(7):6,11-14.
[3]Samanta U,Wilder C,Bahnson B.Crystallization and Preliminary X-Ray Crystallographic Analysis of Human Plasma Platelet Activating Factor Acetylhydrolase[J].Protein&Peptide Letters,2009,16(1):97-100.
[4]Stafforini DM.Biology of platelet-activating factor acetylhydrolase(PAF-AH,lipoprotein associated phospholipase A2)[J].Cardiovascular Drugs&Therapy,2009,23(1):73-83.
[5]中国老年学学会心脑血管病专业委员会.脂蛋白相关磷脂酶A2临床应用专家建议[J].中华心血管病杂志,2015,43(10):9.
[6]夏涵,梁盼盼,府伟灵.量子点荧光标记在生物医学领域的应用[J].中华医院感染学杂志,2012,22(20):4675-4677.
[7]宋国利.量子点的电子结构及量子效应[J].黑龙江大学自然科学学报,2002,19(1):80-83.
[8]林章碧,苏星光,张皓,等.用水溶液中合成的量子点作为生物荧光标记物的研究[J].高等学校化学学报,2003,24(2):216-220.
[9]Bruchez Jr,M.Semiconductor Nanocrystals as Fluorescent Biological Labels[J].Science,1998,281(5385):2013-2016.
[10]Chan WCW,Nie SM.Quantum dot bioconjugates for ultra-sensitive nioso topic detection[J].Science,1998,281(5385):2016-2018.
[11]Shang L,Zhang L,Dong S.Turn-on fluorescent cyanide sensor based on copper ion-modified CdTe quantum dots[J].Analyst,2008,134(1):107-113.
[12]戴尽波.量子点标记免疫技术在食品中小分子有害物检测中的应用[J].食品科学,2016,37(19):296-301.
[13]杨文胜,高明远,白玉白.纳米材料与生物技术[M].北京:化学工业出版社,2005:25.
[14]Cui XD,Primak A,Zarate X,et al.Reproducible measurement of single-molecule conductivity[J].Science,2001,294(5542):571-574.
[15]李金贵,朱奎,徐飞,等.庆大霉素与水溶性CdTe量子点的荧光共振能量转移作用[J].光谱学与光谱分析,2009,29(11):3070-3074.
[16]Chen JX,Chan YH,Yang TL,et al.Spatially selective optical tuning of quantum dot thin film luminescence[J].JAm Chem Soc,2009,131(51):18204-18209.
[17]姚玉才.动脉粥样硬化性疾病的一级预防进展[J].心血管病学进展,2012,33(2):147-149.
[18]Sabatine MS,Morrow DA,Michelle O’Donoghue,et al.Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease[J].Arteriosclerosis Thrombosis&Vascular Biology,2007,27(11):2463.
[19]Bhatti S,Hakeem A,Cilingiroglu M.Lp-PLA2 as a marker of cardiovascular diseases[J].Curr Atheroscler Rep,2010,12(2):140-144.
[2]陈伟伟,王文,隋辉,等.《中国心血管病报告2016》要点解读[J].中华高血压杂志,2017,25(7):6,11-14.
[3]Samanta U,Wilder C,Bahnson B.Crystallization and Preliminary X-Ray Crystallographic Analysis of Human Plasma Platelet Activating Factor Acetylhydrolase[J].Protein&Peptide Letters,2009,16(1):97-100.
[4]Stafforini DM.Biology of platelet-activating factor acetylhydrolase(PAF-AH,lipoprotein associated phospholipase A2)[J].Cardiovascular Drugs&Therapy,2009,23(1):73-83.
[5]中国老年学学会心脑血管病专业委员会.脂蛋白相关磷脂酶A2临床应用专家建议[J].中华心血管病杂志,2015,43(10):9.
[6]夏涵,梁盼盼,府伟灵.量子点荧光标记在生物医学领域的应用[J].中华医院感染学杂志,2012,22(20):4675-4677.
[7]宋国利.量子点的电子结构及量子效应[J].黑龙江大学自然科学学报,2002,19(1):80-83.
[8]林章碧,苏星光,张皓,等.用水溶液中合成的量子点作为生物荧光标记物的研究[J].高等学校化学学报,2003,24(2):216-220.
[9]Bruchez Jr,M.Semiconductor Nanocrystals as Fluorescent Biological Labels[J].Science,1998,281(5385):2013-2016.
[10]Chan WCW,Nie SM.Quantum dot bioconjugates for ultra-sensitive nioso topic detection[J].Science,1998,281(5385):2016-2018.
[11]Shang L,Zhang L,Dong S.Turn-on fluorescent cyanide sensor based on copper ion-modified CdTe quantum dots[J].Analyst,2008,134(1):107-113.
[12]戴尽波.量子点标记免疫技术在食品中小分子有害物检测中的应用[J].食品科学,2016,37(19):296-301.
[13]杨文胜,高明远,白玉白.纳米材料与生物技术[M].北京:化学工业出版社,2005:25.
[14]Cui XD,Primak A,Zarate X,et al.Reproducible measurement of single-molecule conductivity[J].Science,2001,294(5542):571-574.
[15]李金贵,朱奎,徐飞,等.庆大霉素与水溶性CdTe量子点的荧光共振能量转移作用[J].光谱学与光谱分析,2009,29(11):3070-3074.
[16]Chen JX,Chan YH,Yang TL,et al.Spatially selective optical tuning of quantum dot thin film luminescence[J].JAm Chem Soc,2009,131(51):18204-18209.
[17]姚玉才.动脉粥样硬化性疾病的一级预防进展[J].心血管病学进展,2012,33(2):147-149.
[18]Sabatine MS,Morrow DA,Michelle O’Donoghue,et al.Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease[J].Arteriosclerosis Thrombosis&Vascular Biology,2007,27(11):2463.
[19]Bhatti S,Hakeem A,Cilingiroglu M.Lp-PLA2 as a marker of cardiovascular diseases[J].Curr Atheroscler Rep,2010,12(2):140-144.